These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 35388363)

  • 1. The Hippo Signaling Core Components YAP and TAZ as New Prognostic Factors in Lung Cancer.
    Jiang Y; Xie WJ; Chen RW; You WW; Ye WL; Chen H; Chen WX; Xu JP
    Front Surg; 2022; 9():813123. PubMed ID: 35388363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. miR-582-5p Is a Tumor Suppressor microRNA Targeting the Hippo-YAP/TAZ Signaling Pathway in Non-Small Cell Lung Cancer.
    Zhu B; V M; Finch-Edmondson M; Lee Y; Wan Y; Sudol M; DasGupta R
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy.
    Juan WC; Hong W
    Genes (Basel); 2016 Aug; 7(9):. PubMed ID: 27589805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy.
    Vici P; Ercolani C; Di Benedetto A; Pizzuti L; Di Lauro L; Sperati F; Terrenato I; Gamucci T; Natoli C; Di Filippo F; Botti C; Barba M; Mottolese M; De Maria R; Maugeri-Saccà M
    J Exp Clin Cancer Res; 2016 Apr; 35():62. PubMed ID: 27039292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
    Noto A; De Vitis C; Pisanu ME; Roscilli G; Ricci G; Catizone A; Sorrentino G; Chianese G; Taglialatela-Scafati O; Trisciuoglio D; Del Bufalo D; Di Martile M; Di Napoli A; Ruco L; Costantini S; Jakopin Z; Budillon A; Melino G; Del Sal G; Ciliberto G; Mancini R
    Oncogene; 2017 Aug; 36(32):4573-4584. PubMed ID: 28368399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer.
    Horie M; Saito A; Ohshima M; Suzuki HI; Nagase T
    Cancer Sci; 2016 Dec; 107(12):1755-1766. PubMed ID: 27627196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging Role of Hippo-YAP (Yes-Associated Protein)/TAZ (Transcriptional Coactivator with PDZ-Binding Motif) Pathway Dysregulation in Renal Cell Carcinoma Progression.
    Mondal V; Higgins PJ; Samarakoon R
    Cancers (Basel); 2024 Aug; 16(15):. PubMed ID: 39123485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer.
    Di Benedetto A; Mottolese M; Sperati F; Ercolani C; Di Lauro L; Pizzuti L; Vici P; Terrenato I; Sperduti I; Shaaban AM; Sundara-Rajan S; Barba M; Speirs V; De Maria R; Maugeri-Saccà M
    Oncotarget; 2016 Jul; 7(28):43188-43198. PubMed ID: 27248471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The combination of YAP/TAZ predicts the clinical prognosis in patients with cholangiocarcinoma after radical resection].
    Liu Y; Wu Y; Ouyang YS; He JJ; Shen LL; Qi H; Cao F; Chen SG
    Zhonghua Nei Ke Za Zhi; 2021 Jul; 60(7):637-643. PubMed ID: 34619841
    [No Abstract]   [Full Text] [Related]  

  • 10. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
    Jang JW; Kim MK; Bae SC
    Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the Hippo transducer TAZ in association with WNT pathway mutations impacts survival outcomes in advanced gastric cancer patients treated with first-line chemotherapy.
    Melucci E; Casini B; Ronchetti L; Pizzuti L; Sperati F; Pallocca M; De Nicola F; Goeman F; Gallo E; Amoreo CA; Sergi D; Terrenato I; Vici P; Di Lauro L; Diodoro MG; Pescarmona E; Barba M; Mazzotta M; Mottolese M; Fanciulli M; Ciliberto G; De Maria R; Buglioni S; Maugeri-Saccà M
    J Transl Med; 2018 Feb; 16(1):22. PubMed ID: 29402328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Division of Labor between YAP and TAZ in Non-Small Cell Lung Cancer.
    Shreberk-Shaked M; Dassa B; Sinha S; Di Agostino S; Azuri I; Mukherjee S; Aylon Y; Blandino G; Ruppin E; Oren M
    Cancer Res; 2020 Oct; 80(19):4145-4157. PubMed ID: 32816858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of TAZ expression in various cancers: a meta-analysis.
    Feng J; Ren P; Gou J; Li Z
    Onco Targets Ther; 2016; 9():5235-44. PubMed ID: 27601916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role.
    Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YAP/TAZ: a promising target for squamous cell carcinoma treatment.
    Dong X; Meng L; Liu P; Ji R; Su X; Xin Y; Jiang X
    Cancer Manag Res; 2019; 11():6245-6252. PubMed ID: 31360073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma.
    Hayashi H; Uemura N; Zhao L; Matsumura K; Sato H; Shiraishi Y; Baba H
    Front Oncol; 2021; 11():700315. PubMed ID: 34395269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA SFTA1P mediates positive feedback regulation of the Hippo-YAP/TAZ signaling pathway in non-small cell lung cancer.
    Zhu B; Finch-Edmondson M; Leong KW; Zhang X; V M; Lin QXX; Lee Y; Ng WT; Guo H; Wan Y; Sudol M; DasGupta R
    Cell Death Discov; 2021 Nov; 7(1):369. PubMed ID: 34845189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YAP/TAZ for cancer therapy: opportunities and challenges (review).
    Guo L; Teng L
    Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and β1-integrin in conventional osteosarcoma.
    Bouvier C; Macagno N; Nguyen Q; Loundou A; Jiguet-Jiglaire C; Gentet JC; Jouve JL; Rochwerger A; Mattei JC; Bouvard D; Salas S
    Oncotarget; 2016 Oct; 7(40):64702-64710. PubMed ID: 27608849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
    Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
    J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.